Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat

American Journal of Physiology - Renal Physiology

Volumn 315, Issue 3, 2018, Pages F653-F664

  Masuda, Takahiro ^a   Watanabe, Yuko ^a   Fukuda, Keiko ^a   Watanabe, Minami ^a   Onishi, Akira ^a   Ohara, Ken ^a   Imai, Toshimi ^a   Koepsell, Hermann ^b   Muto, Shigeaki ^a   Vallon, Volker ^c   Nagata, Daisuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bioimpedance analysis; Body fluid volume; Diuresis; Natriuresis; SGLT2 inhibition

Indexed keywords

IPRAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM ION; EPITHELIAL SODIUM CHANNEL; GLUCOSIDE; SGLT2 PROTEIN, RAT; SLC5A1 PROTEIN, RAT; SLC9A3 PROTEIN, RAT; SODIUM; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM PROTON EXCHANGE PROTEIN 3; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOIMPEDANCE SPECTROSCOPY; BODY FLUID; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FLUID INTAKE; FOOD INTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPECTROSCOPY; URINARY EXCRETION; URINE VOLUME; ANIMAL; BLOOD; BODY COMPOSITION; DISEASE MODEL; DIURESIS; DRINKING; EATING; ELECTROLYTE BALANCE; METABOLISM; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME FACTOR; TOXICITY; URINE;

ANIMALS; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DIURESIS; DRINKING; EATING; EPITHELIAL SODIUM CHANNELS; GLUCOSIDES; MALE; NATRIURESIS; RATS, SPRAGUE-DAWLEY; SODIUM; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SODIUM-HYDROGEN EXCHANGER 3; THIOPHENES; TIME FACTORS; WATER-ELECTROLYTE BALANCE;

EID: 85052656968     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00143.2018     Document Type: Article

References (51)

1. Balen D, Ljubojevic M, Breljak D, Brzica H, Zlender V, Koepsell H, Sabolic I. Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol 295: C475-C489, 2008. doi:10.1152/ajpcell.00180.2008.
2. Chapman ME, Hu L, Plato CF, Kohan DE. Bioimpedance spectroscopy for the estimation of body fluid volumes in mice. Am J Physiol Renal Physiol 299: F280-F283, 2010. doi:10.1152/ajprenal.00113.2010.
3. Edwards A, Castrop H, Laghmani K, Vallon V, Layton AT. Effects of NKCC2 isoform regulation on NaCl transport in thick ascending limb and macula densa: a modeling study. Am J Physiol Renal Physiol 307: F137-F146, 2014. doi:10.1152/ajprenal.00158.2014.
4. Fu Y, Gerasimova M, Batz F, Kuczkowski A, Alam Y, Sanders PW, Ronzaud C, Hummler E, Vallon V. PPAR+ agonist-induced fluid retention depends on _ENaC expression in connecting tubules. Nephron 129: 68-74, 2015. doi:10.1159/000370254.
5. Fu Y, Gerasimova M, Mayoux E, Masuda T, Vallon V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration (Abstract). Diabetes 63, Suppl 1: A132, 2014.
6. Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U, Forbes JM. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep 6: 26428, 2016. [Erratum in Sci Rep 6: 28124, 2016.] 10.1038/srep26428.
7. Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307: F317-F325, 2014. doi:10.1152/ajprenal.00145.2014.
8. González AA, Céspedes C, Villanueva S, Michea L, Vio CP. E Prostanoid-1 receptor regulates renal medullary alphaENaC in rats infused with angiotensin II. Biochem Biophys Res Commun 389: 372-377, 2009. doi:10.1016/j.bbrc.2009.08.157.
9. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61: 187-196, 2012. doi:10.2337/db11-1029.
10. Hayashi M, Arima H, Goto M, Banno R, Watanabe M, Sato I, Nagasaki H, Oiso Y. Vasopressin gene transcription increases in response to decreases in plasma volume, but not to increases in plasma osmolality, in chronically dehydrated rats. Am J Physiol Endocrinol Metab 290: E213-E217, 2006. doi:10.1152/ajpendo.00158.2005.
11. Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T, Tamori Y. Impact of the 8-week administration of tofogliflozin for glycemic control and body composition in Japanese patients with type 2 diabetes mellitus. Intern Med 55: 3239-3245, 2016. doi:10.2169/internalmedicine.55.6367.
12. Huang DY, Pfaff I, Serradeil-Le Gal C, Vallon V. Acute renal response to the non-peptide vasopressin V2-receptor antagonist SR 121463B in anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 362: 201-207, 2000. doi:10.1007/s002100000282.
13. Huang X, Dorhout Mees E, Vos P, Hamza S, Braam B. Everything we always wanted to know about furosemide but were afraid to ask. Am J Physiol Renal Physiol 310: F958 -F971, 2016. doi:10.1152/ajprenal.00476.2015.
14. Imai T, Akimoto T, Ito C, Masuda T, Nagata D. Management of diabetes associated with nephrotic syndrome: therapeutic potential of dapagliflozin for protracted volume retention. Drug Target Insights 9: 29-31, 2015. doi:10.4137/DTI.S31710.
15. Ito M, Tanaka T. The anticipated renoprotective effects of sodiumglucose cotransporter 2 inhibitors. Intern Med 57: 2105-2114, 2018. doi:10.2169/internalmedicine.9842-17.
16. Iwazu Y, Muto S, Fujisawa G, Nakazawa E, Okada K, Ishibashi S, Kusano E. Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis. Hypertension 51: 749-754, 2008. doi:10.1161/HYPERTENSIONAHA.107.104901.
17. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na_/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93: 397-404, 1994. doi:10.1172/JCI116972.
18. Kemter E, Rathkolb B, Bankir L, Schrewe A, Hans W, Landbrecht C, Klaften M, Ivandic B, Fuchs H, Gailus-Durner V, Hrabé de Angelis M, Wolf E, Wanke R, Aigner B. Mutation of the Na(+)-K(+)-2Cl(-) cotransporter NKCC2 in mice is associated with severe polyuria and a urea-selective concentrating defect without hyperreninemia. Am J Physiol Renal Physiol 298: F1405-F1415, 2010. doi:10.1152/ajprenal.00522.2009.
19. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol 15: 157, 2016. doi:10.1186/s12933-016-0473-7.
20. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15: 853-862, 2013. doi:10.1111/dom.12127.
21. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 13: 148, 2014. doi:10.1186/s12933-014-0148-1.
22. Maric-Bilkan C, Flynn ER, Chade AR. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. Am J Physiol Renal Physiol 302: F308-F315, 2012. doi:10.1152/ajprenal.00421.2011.
23. Masuda T, Fu Y, Eguchi A, Czogalla J, Rose MA, Kuczkowski A, Gerasimova M, Feldstein AE, Scadeng M, Vallon V. Dipeptidyl peptidase IV inhibitor lowers PPAR_ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention. Am J Physiol Endocrinol Metab 306: E388-E398, 2014. doi:10.1152/ajpendo.00124.2013.
24. Masuda T, Muto S, Fujisawa G, Iwazu Y, Kimura M, Kobayashi T, Nonaka-Sarukawa M, Sasaki N, Watanabe Y, Shinohara M, Murakami T, Shimada K, Kobayashi E, Kusano E. Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 302: H1871-H1883, 2012. doi:10.1152/ajpheart.00663.2011.
25. Masuda T, Ohara K, Murakami T, Imai T, Nakagawa S, Okada M, Miki A, Myoga A, Onishi A, Sekiguchi C, Miyazawa Y, Akimoto T, Saito O, Muto S, Nagata D. Sodium-glucose cotransporter 2 inhibition with dapagliflozin ameliorates extracellular volume expansion in diabetic kidney disease patients. POJ Diabetes Obesity Management 1: 1-8, 2017.
26. Montiel V, Leon Gomez E, Bouzin C, Esfahani H, Romero Perez M, Lobysheva I, Devuyst O, Dessy C, Balligand JL. Genetic deletion of aquaporin-1 results in microcardia and low blood pressure in mouse with intact nitric oxide-dependent relaxation, but enhanced prostanoids-dependent relaxation. Pflugers Arch 466: 237-251, 2014. doi:10.1007/s00424-013-1325-x.
27. Mu S, Shimosawa T, Ogura S, Wang H, Uetake Y, Kawakami-Mori F, Marumo T, Yatomi Y, Geller DS, Tanaka H, Fujita T. Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med 17: 573-580, 2011. [Errata in Nat Med 17:1020, 2011; Nat Med 18: 630, 2012.] 10.1038/nm.2337.
28. Pavlov TS, Staruschenko A. Involvement of ENaC in the development of salt-sensitive hypertension. Am J Physiol Renal Physiol 313: F135-F140, 2017. doi:10.1152/ajprenal.00427.2016.
29. Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G. Functional role of glucose metabolism, osmotic stress, and sodiumglucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25: 2028-2039, 2014. doi:10.1681/ASN.2013060588.
30. Rahman A, Kittikulsuth W, Fujisawa Y, Sufiun A, Rafiq K, Hitomi H, Nakano D, Sohara E, Uchida S, Nishiyama A. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens 34: 893-906, 2016. doi:10.1097/HJH.0000000000000871.
31. Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, Drucker DJ, Vallon V. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 303: F963-F971, 2012. doi:10.1152/ajprenal.00259.2012.
32. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306: F188-F193, 2014. doi:10.1152/ajprenal.00518.2013.
33. Rieg T, Tang T, Uchida S, Hammond HK, Fenton RA, Vallon V. Adenylyl cyclase 6 enhances NKCC2 expression and mediates vasopressin- induced phosphorylation of NKCC2 and NCC. Am J Pathol 182: 96-106, 2013. doi:10.1016/j.ajpath.2012.09.014.
34. Sabolic´ I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H. Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 302: C1174-C1188, 2012. doi:10.1152/ajpcell.00450.2011.
35. Sasase T, Ohta T, Masuyama T, Yokoi N, Kakehashi A, Shinohara M. The spontaneously diabetic torii rat: an animal model of nonobese type 2 diabetes with severe diabetic complications. J Diabetes Res 2013: 976209, 2013. doi:10.1155/2013/976209.
36. Shinohara M, Masuyama T, Shoda T, Takahashi T, Katsuda Y, Komeda K, Kuroki M, Kakehashi A, Kanazawa Y. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 1: 89-100, 2000. doi:10.1155/EDR.2000.89.
37. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamideinduced mildly diabetic mice. J Pharmacol Sci 120: 36-44, 2012. doi:10.1254/jphs.12089FP.
38. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 385: 423-436, 2012. doi:10.1007/s00210-011-0713-z.
39. Takeshige Y, Fujisawa Y, Rahman A, Kittikulsuth W, Nakano D, Mori H, Masaki T, Ohmori K, Kohno M, Ogata H, Nishiyama A. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens Res 39: 415-422, 2016. doi:10.1038/hr.2016.2.
40. Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, Nakamori S, Fujimoto N, Fujii E, Yamada N, Ito M. Diuretic effects of sodiumglucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol 201: 1-3, 2015. [Erratum in Int J Cardiol 206: 173, 2016.] 10.1016/j.ijcard.2015.07.072.
41. Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, Arakawa K, Togo M, Inagaki N, Kaku K. Factors affecting canagliflozin- induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther 34: 436-451, 2017. doi:10.1007/s12325-016-0457-8.
42. Umenishi F, Schrier RW. Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity- responsive element in the AQP1 gene. J Biol Chem 278: 15765-15770, 2003. doi:10.1074/jbc.M209980200.
43. Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306: F194-F204, 2014. doi:10.1152/ajprenal.00520.2013.
44. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104-112, 2011. doi:10.1681/ASN.2010030246.
45. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304: F156-F167, 2013. doi:10.1152/ajprenal.00409.2012.
46. Vallon V, Schwark JR, Richter K, Hropot M. Role of Na(+)/H(+) exchanger NHE3 in nephron function: micropuncture studies with S3226, an inhibitor of NHE3. Am J Physiol Renal Physiol 278: F375-F379, 2000. doi:10.1152/ajprenal.2000.278.3.F375.
47. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60: 215-225, 2017. doi:10.1007/s00125-016-4157-3.
48. Vallon V, Verkman AS, Schnermann J. Luminal hypotonicity in proximal tubules of aquaporin-1-knockout mice. Am J Physiol Renal Physiol 278: F1030-F1033, 2000. doi:10.1152/ajprenal.2000.278.6.F1030.
49. West CA, Sasser JM, Baylis C. The enigma of continual plasma volume expansion in pregnancy: critical role of the renin-angiotensin-aldosterone system. Am J Physiol Renal Physiol 311: F1125-F1134, 2016. doi:10.1152/ajprenal.00129.2016.
50. Yamada K, Nakayama H, Yoshinobu S, Kawano S, Tsuruta M, Nohara M, Hasuo R, Akasu S, Tokubuchi I, Wada N, Hirao S, Iwata S, Kaku H, Tajiri Y. Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring. J Diabetes Investig 6: 699-707, 2015. doi:10.1111/jdi.12370.
51. Yang LE, Maunsbach AB, Leong PK, McDonough AA. Differential traffic of proximal tubule Na+ transporters during hypertension or PTH: NHE3 to base of microvilli vs. NaPi2 to endosomes. Am J Physiol Renal Physiol 287: F896-F906, 2004. doi:10.1152/ajprenal.00160.2004.